U
Sonendo, Inc. SONX
$0.50 $0.1751.52% OTC PK
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

Company Overview

Sonendo, Inc. is a medical technology company focused on dental care, specifically advanced solutions for root canal therapy. The company operates within the dental devices and medical technology industries and is best known for developing the GentleWave System, a technology designed to clean and disinfect the root canal system using fluid dynamics rather than traditional mechanical instrumentation. Sonendo’s primary revenue driver has historically been the sale of capital equipment, consumables, and related services associated with the GentleWave platform, with customers primarily consisting of endodontists and general dentists.

Sonendo positions itself as a differentiated provider in endodontics by emphasizing improved clinical outcomes, reduced procedure time, and enhanced patient experience compared to conventional root canal methods. The company was founded in 2012 and later went public in 2021. Following its IPO, Sonendo expanded commercialization efforts but faced financial and liquidity challenges. Public disclosures indicate that the company initiated Chapter 11 bankruptcy proceedings in 2023, reflecting a significant inflection point in its corporate evolution. Details regarding post-bankruptcy structure and long-term continuity remain limited in publicly available filings.

Business Operations

Sonendo’s operations have been centered around a single primary operating segment focused on endodontic technology. This segment encompasses the development, manufacturing, marketing, and servicing of the GentleWave System, including procedure instruments, consumables, and service contracts that generate recurring revenue. Historically, revenue has been driven by system placements and ongoing utilization of disposable procedure instruments by dental practices.

The company has conducted operations in both domestic and international markets, with commercial activities in the United States representing the majority of revenue prior to bankruptcy. Sonendo has relied on proprietary technology, intellectual property, and specialized manufacturing processes to support its platform. Public filings reference the use of third-party suppliers and contract manufacturers rather than vertically integrated production. Information on active subsidiaries or joint ventures following the Chapter 11 filing is data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, Sonendo aimed to expand adoption of the GentleWave System through increased practitioner education, clinical data generation, and broader commercial reach. Prior to its financial restructuring, the company invested heavily in sales force expansion, research and development, and clinical studies to support claims of superior outcomes compared to traditional root canal procedures.

Sonendo’s investment strategy did not historically include a diversified portfolio of acquisitions; instead, capital allocation was concentrated on internal technology development and commercialization. Public disclosures do not indicate material acquisitions of other companies. Following the bankruptcy filing, information regarding ongoing investments, asset sales, or technology licensing arrangements is data inconclusive based on available public sources, as updated post-restructuring disclosures are limited.

Geographic Footprint

Sonendo has been headquartered in the United States, with its principal executive offices historically located in California. The company’s core commercial market has been North America, particularly the U.S. dental specialty market, which represents the largest installed base for the GentleWave System.

Internationally, Sonendo has reported limited but growing presence in parts of Europe and Asia-Pacific through distributors and select direct sales activities. These markets have represented a smaller portion of overall revenue compared to the U.S. Public filings prior to bankruptcy describe international expansion as a long-term opportunity rather than a primary revenue driver. The extent of Sonendo’s current global operations after restructuring is data inconclusive based on available public sources.

Leadership & Governance

Sonendo was founded by industry professionals with backgrounds in medical devices and dental technology. Leadership disclosures prior to the company’s Chapter 11 filing identify the following executives as key members of management:

  • Bjarne BergheimPresident and Chief Executive Officer
  • Thomas DeRosaChief Financial Officer
  • Brent EastwoodChief Commercial Officer
  • Jeffrey BriceChief Technology Officer

The leadership team has articulated a strategy centered on clinical innovation, evidence-based dentistry, and practitioner-focused solutions. Governance and board oversight have followed public company standards as outlined in SEC filings, though changes to leadership and board composition may have occurred in connection with bankruptcy proceedings. Current leadership structure following restructuring is data inconclusive based on available public sources.

Data complied by narrative technology. May contain errors

Top Tech Stocks
See All »
B
NVDA NASDAQ $208.60
B
AAPL NASDAQ $269.65
B
MU NASDAQ $513.68
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $127.42
B
Top Financial Stocks
See All »
Top Energy Stocks
See All »
B
ENB.TO TSX $75.40
B
ENB NYSE $53.11
Top Health Care Stocks
See All »
B
LLY NYSE $851.32
B
JNJ NYSE $227.24
B
AMGN NASDAQ $337.16
Top Real Estate Stocks
See All »
B
CBRE NYSE $142.74